Table 6.

Results of Phase 2 Clinical Trials of Ipilimumab Monotherapy in Patients With Unresectable Stage III or IV Melanoma

Endpoint	Wolchoka (n = 72) %	Hershb (n = 37) %	O’Dayc (n = 155) %	Weberd (n = 57) %
Best overall response rate	4.2	5.4	5.8	15.8
Complete response	NR	0	0	0
Partial response	NR	5.4	5.8	15.8
Stable disease	NR	16.2	21	19.3
Progressive disease	NR	75.7	56	50.8

^aIpilimumab 3 mg/kg in previously treated patients.

^bIpilimumab 3 mg/kg in previously untreated patients.

^cIpilimumab 10 mg/kg in previously treated patients.

^dIpilimumab 10 mg/kg in previously treated (72%) and untreated (28%) patients.

NR = not reported.

Data from references 36–39.